Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [131I]Sodium Iodide.

IF 1.5 4区医学 Q3 PHARMACOLOGY & PHARMACY

Current radiopharmaceuticals Pub Date : 2025-05-06 DOI:10.2174/0118744710374569250415095218

Daniel M Machado, Daniel A Bulzico, Lídia F Fontes, Rossana C R de Mello, Simone Basso Locatelli, Priscilla B Pujatti

{"title":"Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [131I]Sodium Iodide.","authors":"Daniel M Machado, Daniel A Bulzico, Lídia F Fontes, Rossana C R de Mello, Simone Basso Locatelli, Priscilla B Pujatti","doi":"10.2174/0118744710374569250415095218","DOIUrl":null,"url":null,"abstract":"Background: The ideal [131I]Sodium Iodide activity for intermediate-risk thyroid cancer treatment is still uncertaindue to the high heterogeneity of this disease in these patients.Objective: The objective of this study is to compare the biochemical responses to radioiodine therapy (RIT) of intermediate-risk thyroid cancer patients administered [131I]Sodium Iodide at 3700 MBq (100 mCi) and 5550 MBq (150 mCi) activities.Methods: A retrospective study was conducted by reviewing the medical records of intermediate- risk thyroid cancer patients who received RIT between 2016 and 2020 at a reference cancer hospital in Brazil. Sociodemographic and clinical data were evaluated at the time of diagnosis. Clinical data during two years of follow-up were reviewed, and biochemical responses were determined according to the American Thyroid Association (ATA, 2015 version). Responses to 3700 MBq (100 mCi) and 5550 MBq (150 mCi) of [131I]Sodium Iodide were compared.Results: No significant statistical differences were observed concerning the biochemical therapeutic responses of patients treated with 3700 MBq or 5550 MBq (p = 0.088). The presence of nodal metastasis and positive pre-RIT thyroglobulin did not influence biochemical responses to radioiodine.Conclusion: Intermediate risk thyroid-cancer patients presented similar therapeutic responses to 3700 MBq and 5550 MBq [131I]Sodium Iodide activities.","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0118744710374569250415095218","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The ideal [131I]Sodium Iodide activity for intermediate-risk thyroid cancer treatment is still uncertaindue to the high heterogeneity of this disease in these patients.

Objective: The objective of this study is to compare the biochemical responses to radioiodine therapy (RIT) of intermediate-risk thyroid cancer patients administered [131I]Sodium Iodide at 3700 MBq (100 mCi) and 5550 MBq (150 mCi) activities.

Methods: A retrospective study was conducted by reviewing the medical records of intermediate- risk thyroid cancer patients who received RIT between 2016 and 2020 at a reference cancer hospital in Brazil. Sociodemographic and clinical data were evaluated at the time of diagnosis. Clinical data during two years of follow-up were reviewed, and biochemical responses were determined according to the American Thyroid Association (ATA, 2015 version). Responses to 3700 MBq (100 mCi) and 5550 MBq (150 mCi) of [131I]Sodium Iodide were compared.

Results: No significant statistical differences were observed concerning the biochemical therapeutic responses of patients treated with 3700 MBq or 5550 MBq (p = 0.088). The presence of nodal metastasis and positive pre-RIT thyroglobulin did not influence biochemical responses to radioiodine.

Conclusion: Intermediate risk thyroid-cancer patients presented similar therapeutic responses to 3700 MBq and 5550 MBq [131I]Sodium Iodide activities.

查看原文本刊更多论文

3700或5550 MBq [131I]碘化钠对中度分化甲状腺癌生化反应的真实世界数据

背景：由于中危甲状腺癌患者的高异质性，碘化钠治疗中危甲状腺癌的理想[131I]活性仍不确定。目的：本研究的目的是比较中等风险甲状腺癌患者在3700 MBq （100 mCi）和5550 MBq （150 mCi）碘化钠剂量下对放射性碘治疗（RIT）的生化反应。方法：回顾性研究了2016年至2020年在巴西某肿瘤医院接受RIT治疗的中危甲状腺癌患者的病历。在诊断时评估社会人口学和临床资料。回顾了两年随访期间的临床数据，并根据美国甲状腺协会（ATA， 2015版）确定生化反应。比较3700 MBq （100 mCi）和5550 MBq (150 mCi) [131I]碘化钠的反应。结果：3700 MBq组与5550 MBq组的生化治疗效果差异无统计学意义（p = 0.088）。淋巴结转移和rit前甲状腺球蛋白阳性不影响放射性碘的生化反应。结论：3700 MBq和5550 MBq [131I]碘化钠治疗中危甲状腺癌患者疗效相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current radiopharmaceuticals PHARMACOLOGY & PHARMACY-

CiteScore

3.20

自引率

4.30%

发文量